Publications

Export 56 results:
Sort by: [ Author  (Desc)] Title Type Year
A B C D E F G H I J K L M N O P [Q] R S T U V W X Y Z   [Show ALL]
Q
Qutaany, A. Z. E., A. H. El Bastawissy, and O. Hegazy, "A technique for mutual inconsistencies detection and resolution in virtual data integration environment", Informatics and Systems (INFOS), 2010 The 7th International Conference on: IEEE, pp. 1–8, 2010. Abstract
n/a
Qutaany, A. Z. E., A. H. El Bastawissy, and O. Hegazy, "A technique for mutual inconsistencies detection and resolution in virtual data integration environment", Informatics and Systems (INFOS), 2010 The 7th International Conference on: IEEE, pp. 1–8, 2010. Abstract
n/a
Qutaany, A. Z. E., A. E. Bastawissy, and O. Hegazy, "A Technique for Mutual Inconsistencies Detection and Resolution in Data Integration Framework", INFOS, Cairo - Egypt, March, 2010.
Qureshi, A. I., F. Abd-Allah, F. Al-Senani, E. Aytac, A. Borhani-Haghighi, A. Ciccone, C. R. Gomez, E. Gurkas, C. Y. Hsu, and V. Jani, "Management of acute ischemic stroke in patients with COVID-19 infection: Insights from an international panel", The American Journal of Emergency Medicine: Elsevier, 2020. Abstract
n/a
Qureshi, A. I., F. Abd-Allah, A. Aleu, J. J. Connors, R. A. Hanel, A. E. Hassan, H. M. Hussein, N. A. Janjua, R. Khatri, J. F. Kirmani, et al., "Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials: A report from the Working Group of International Congress of Interventional Neurology.", Journal of vascular and interventional neurology, vol. 7, issue 1, pp. 56-75, 2014 May. Abstract

OBJECTIVE: The results of Interventional Management of Stroke (IMS) III, Magnetic Resonance and REcanalization of Stroke Clots Using Embolectomy (MR RESCUE), and SYNTHESIS EXPANSION trials are expected to affect the practice of endovascular treatment for acute ischemic stroke. The purpose of this report is to review the components of the designs and methods of these trials and to describe the influence of those components on the interpretation of trial results.

METHODS: A critical review of trial design and conduct of IMS III, MR RESCUE, and SYNTHESIS EXPANSION is performed with emphasis on patient selection, shortcomings in procedural aspects, and methodology of data ascertainment and analysis. The influence of each component is estimated based on published literature including multicenter clinical trials reporting on endovascular treatment for acute ischemic stroke and myocardial infarction.

RESULTS: We critically examined the time interval between symptom onset and treatment and rates of angiographic recanalization to differentiate between "endovascular treatment" and "parameter optimized endovascular treatment" as it relates to the IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials. All the three trials failed to effectively test "parameter optimized endovascular treatment" due to the delay between symptom onset and treatment and less than optimal rates of recanalization. In all the three trials, the magnitude of benefit with endovascular treatment required to reject the null hypothesis was larger than could be expected based on previous studies. The IMS III and SYNTHESIS EXPANSION trials demonstrated that rates of symptomatic intracerebral hemorrhages subsequent to treatment are similar between IV thrombolytics and endovascular treatment in matched acute ischemic stroke patients. The trials also indirectly validated the superiority/equivalence of IV thrombolytics (compared with endovascular treatment) in patients with minor neurological deficits and those without large vessel occlusion on computed tomographic/magnetic resonance angiography.

CONCLUSIONS: The results do not support a large magnitude benefit of endovascular treatment in subjects randomized in all the three trials. The possibility that benefits of a smaller magnitude exist in certain patient populations cannot be excluded. Large magnitude benefits can be expected with implementation of "parameter optimized endovascular treatment" in patients with ischemic stroke who are candidates for IV thrombolytics.

Qureshi, A. I., F. Abd-Allah, F. Alsenani, E. Aytac, A. Borhani-Haghighi, A. Ciccone, C. R. Gomez, E. Gurkas, C. Y. Hsu, and V. Jani, "Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel", International Journal of Stroke: SAGE Publications Sage UK: London, England, pp. 1747493020923234, 2020. Abstract
n/a
Quraishy, S. A., R. Abdel-Gaber, M. A. Dkhil, A. - A. S. Abdel-Baki, M. Alotaibi, W. Alhafidh, and N. Al-Houshany, "Detection of Raillietina saudiae from the domestic pigeon in Saudi Arabia through 18S and 28S rDNA genes", Letters in Applied Microbiology, 2020.
Quitmann, E., M. Fischer, Amgad El-Deib, and S. Engelken, "Anticipating Power System Needs in Response to the Global Energy Transition", CIGRE Conference, Paris, June, 2015.
Quiroz-Mercado, H., J. Rivera-Sempertegui, T. A. Macky, P. Navarro-López, L. Griselda-Alvarez, N. Ibarra-Ponce, and D. Moreno-Páramo, "Performing vitreous biopsy by perfluorocarbon-perfused vitrectomy.", American journal of ophthalmology, vol. 140, issue 6, pp. 1161-3, 2005 Dec. Abstract

PURPOSE: To evaluate the safety and efficacy of perfluorocarbon-perfused vitrectomy (PCPV) as a novel technique in obtaining a large undiluted vitreous biopsy.

DESIGN: Cross-sectional interventional study.

METHODS: Patients with undiagnosed posterior uveitis scheduled for vitreous biopsy underwent PCPV. A syringe containing 5 ml of perfluorocarbon liquid (PCL) was connected to the infusion line. Aspiration of the central and superior vitreous was initiated with simultaneous infusion of the PCL.

RESULTS: Twenty eyes of 20 patients were included in this study. The mean +/- SD amount of PCL used in each eye was 4.50 +/- 0.69 ml. The volume of vitreous sample obtained in each eye was 2.25 +/- 0.413 ml. No complications occurred.

CONCLUSIONS: PCPV is a safe and effective method for obtaining large undiluted vitreous biopsy.

Quirke, J. C. K., P. Rajasekaran, V. A. Sarpe, A. Sonousi, I. Osinnii, M. Gysin, K. Haldimann, Q. - J. Fang, D. Shcherbakov, S. N. Hobbie, et al., "Apralogs: Apramycin 5-O-Glycosides and Ethers with Improved Antibacterial Activity and Ribosomal Selectivity and Reduced Susceptibility to the Aminoacyltransferase (3)-IV Resistance Determinant", Journal of the American Chemical Society, vol. 142, issue 1: American Chemical Society, pp. 530 - 544, 2020. AbstractWebsite

n/a

Quirke, J. C. K., G. C. Sati, A. Sonousi, M. Gysin, K. Haldimann, E. C. Böttger, A. Vasella, S. N. Hobbie, and D. Crich, "Structure-Activity Relationships for 5′′ Modifications of 4,5-Aminoglycoside Antibiotics", ChemMedChem, vol. n/a, issue n/a: John Wiley & Sons, Ltd, pp. e202200120, 2022. AbstractWebsite

Abstract Modification at the 5??-position of 4,5-disubstituted aminoglycoside antibiotics (AGAs) to circumvent inactivation by aminoglycoside modifying enzymes (AMEs) is well known. Such modifications, however, unpredictably impact activity and affect target selectivity thereby hindering drug development. A survey of 5??-modifications of the 4,5-AGAs and the related 5-O-furanosyl apramycin derivatives is presented. In the neomycin and the apralog series, all modifications were well-tolerated, but other 4,5-AGAs require a hydrogen bonding group at the 5??-position for maintenance of antibacterial activity. The 5??-amino modification resulted in parent-like activity, but reduced selectivity against the human cytosolic decoding A site rendering this modification unfavorable in paromomycin, propylamycin, and ribostamycin. Installation of a 5??-formamido group and, to a lesser degree, a 5??-ureido group resulted in parent-like activity without loss of selectivity. These lessons will aid the design of next-generation AGAs capable of circumventing AME action while maintaining high antibacterial activity and target selectivity.

Quinlan, J., A. Zahran, and C. Sreenan, "SDC: Scalable description coding for adaptive streaming media", Packet Video Workshop (PV), 2012 19th International: IEEE, pp. 59–64, 2012. Abstract
n/a
Quinlan, J. J., A. H. Zahran, and C. J. Sreenan, "ALD: Adaptive Layer Distribution for Scalable Video", ACM MMSys 2013, Oslo, Norway, Feb 2013. AbstractCU-PDF

Bandwidth constriction and datagram loss are prominent issues that affect the perceived quality of streaming video over lossy networks, such as wireless. The use of layered video coding seems attractive as a means to alleviate these issues, but its adoption has been held back in large part by the inherent priority assigned to the critical lower layers and the consequences for quality that result from their loss. The proposed use of forward error correction (FEC) as a solution only further burdens the bandwidth availability and can negate the perceived benefits of increased stream quality. In this paper, we propose Adaptive Layer Distribution (ALD) as a novel scalable media delivery technique that optimises the tradeoff between the streaming bandwidth and error resiliency. ALD is based on the principle of layer distribution, in which the critical stream data is spread amongst all datagrams thus lessening the impact on quality due to network losses. Additionally, ALD provides a parameterised mechanism for dynamic adaptation of the scalable video, while providing increased resilience to the highest quality layers. Our experimental results show that ALD improves the perceived quality and also reduces the bandwidth demand by up to 36% in comparison to the well-known Multiple Description Coding (MDC) technique.

Quinlan, J., A. Zahran, and C. Sreenan, "CMSE: A Network Element for Assistive Media Steaming", IT&T, Coek, Ireland, Mar 2012. Abstract

n/a

Qudrat-Ullah, H., M. M. Saleh, and E. A. Bahaa, "Fish Bank ILE An interactive learning laboratory to improve understanding of The Tragedy of Commons a common behaviour of complex dynamic systems", Proceedings of 15th International System Dynamics Conference Istanbul Turkey, 1997. Abstract
n/a
Qubati, L. A., S. Khattab, and I. Farag, "Survey on End-to-End Verifiable Cryptographic Voting Systems.", International Journal of Computer Applications, vol. 100, 2014. AbstractWebsite

n/a

Quasti, A. H., and W. I. Hassan, "Theoretical investigation of the dispersion interaction in argon dimer and trimer", Journal of Biophysical Chemistry, vol. 4, pp. 91-101, 2013. argon.pdf
Quartuccio, L., M. Isola, L. Corazza, M. Ramos-Casals, S. Retamozo, G. M. Ragab, M. N. Zoheir, M. A. - M. El-Menyawi, M. N. Salem, D. Sansonno, et al., "Validation of the classification criteria for cryoglobulinaemic vasculitis.", Rheumatology (Oxford, England), vol. 53, issue 12, pp. 2209-13, 2014 Dec. Abstract

OBJECTIVE: The aim of this study was to validate the classification criteria for cryoglobulinaemic vasculitis (CV).

METHODS: Twenty-three centres were involved. New patients with CV (group A) and controls, i.e. subjects with serum cryoglobulins but lacking CV based on the gold standard of clinical judgment (group B) and subjects without cryoglobulins but with clinical features that can be observed in the course of CV (group C), were studied. Positivity of serum cryoglobulins was necessary for CV classification. Sensitivity and specificity of the criteria were calculated by comparing group A vs group B. The group A vs group C comparison was done to demonstrate the possible diagnostic utility of the criteria.

RESULTS: The study included 268 patients in group A, 182 controls in group B and 193 controls in group C (small vessel vasculitis, 51.8%). The questionnaire (at least 2/3 positive answers) showed 89.0% sensitivity and 93.4% specificity; the clinical item (at least 3/4 clinical involvement) showed 75.7% sensitivity and 89.0% specificity and the laboratory item (at least 2/3 laboratory data) showed 80.2% sensitivity and 62.4% specificity. The sensitivity and specificity of the classification criteria (at least 2/3 positive items) were 89.9% and 93.5%, respectively. The comparison of group A with group C demonstrated the clinical utility of the criteria in differentiating CV from CV mimickers.

CONCLUSION: Classification criteria for CV were validated in a second, large, international study confirming good sensitivity and specificity in a complex systemic disease.

Quartuccio, L., M. Isola, L. Corazza, S. Retamozo, M. A. - M. El-Menyawi, E. Gremese, M. Sebastiani, N. Pipitone, T. Urraro, V. Conteduca, et al., "Validation Study Of The International Classification Criteria For The Cryoglobulinemic Vasculitis", ARTHRITIS AND RHEUMATISM, vol. 65, pp. S1123–S1124, 2013. Abstract
n/a
Quartuccio, L., M. Isola, L. Corazza, M. Ramos-Casals, S. Retamozo, G. M. Ragab, M. N. Zoheir, M. A. - M. El-Menyawi, M. N. Salem, and D. Sansonno, "Validation of the classification criteria for cryoglobulinaemic vasculitis", Rheumatology, vol. 53, issue 12: Oxford University Press, pp. 2209-2213, 2014. Abstract
n/a
Quartuccio, L., L. Corazza, M. Ramos-Casals, S. Retamozo, G. M. Ragab, G. Ferraccioli, E. Gremese, A. Tzioufas, M. Voulgarelis, D. Vassilopoulos, et al., "OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins", Annals of the Rheumatic Diseases, vol. 74, issue Suppl 2, pp. 175-176, June 1, 2015. AbstractWebsite

Background Serum cryoglobulins (SC) may be found in many diseases (1), and the presence of serum cryoglobulins is a known risk factor for lymphoma evolution in some non malignant diseases.Objectives The aim of this study was to distiguish the role of cryoglobulinemic vasculitis (CV), classified according to the recent validated criteria (1,2), and primary Sjögren's syndrome (pSS) as risk factors of lymphoma in patients positive serum cryoglobulins. Importantly, SC, CV and pSS may occur together.Methods 950 charts from consecutive patients with positive SC were evaluated. Patients carrying both pSS and HCV infection, as well as incomplete charts, were excluded.Results 657 patients with SC were selected, 374 with CV and 283 without CV, according to the published criteria (2,3). PSS, classified according to the American-European Group Criteria was present in 96 patients (44 with CV, 52 without). Lymphoma was reported in 61/657 (9.8%) patients with SC. Among them, CV was present in 44/61 (72,1%; 14 also with pSS), and pSS in 17/61 (27,9%; and 14/17 had CV). Patients with SC with CV showed an higher prevalence of lymphoma than patients with SC without CV (44/374, 11.5% vs.17/283, 6.3%; p=0.025, OR=1.93 [95%IC: 1.08-3.39]. Patients with pSS, SC and CV also showed a higher prevalence of lymphoma than patients with pSS, SC but without CV (14/44, 31.8% vs. 3/52, 7.4%; p=0.001, OR=7.62 [95%CI 2.02-28.74]. CV and pSS were confirmed as independent risk factor for lymphoma by multivariate analysis (OR 2,18 95%CI 1,18-3,83, p=0,012; OR 2,65 95%CI 1,04-6,76, p=0,042, respectively). Infection by the hepatitis C virus (HCV) was detected in 467/561 (83,2%) patients with SC without pSS, and did not statistically predispose to lymphoma when associated with CV in this subset (p=1,0).Conclusions Cryoglobulinemic vasculitis and pSS are independent risk factors for lymphoma in patients with evidence of SC. Patients with both the conditions (CV and pSS) have the highest risk. In the follow-up of SC positive patients, a very high attention should be deserved to pSS, in particular when CV is present.ReferencesDe Vita S, et al. Ann Rheum Dis. 2011; 2) Quartuccio L, et al. Rheumatology (Oxford). 2014Disclosure of Interest None declared